The aim of this study was to perform a pooled analysis of five clinical studies to evaluate the efficacy, organ-protective effects, and safety of esaxerenone in hypertensive patients with CKD (defined as a urine albumin-to-creatinine ratio [UACR] ≥30 mg/gCr) according to the presence or absence of comorbid T2DM. The gene discussed is ALB; the disease is type 2 diabetes mellitus.